Immunoglobulin, Antiserum, Antibody, Or Antibody Fragment, Except Conjugate Or Complex Of The Same With Nonimmunoglobulin Material Patents (Class 424/130.1)
  • Patent number: 11326149
    Abstract: Organs-on-chips are microfluidic devices for culturing living cells in micrometer sized chambers in order to model physiological functions of tissues and organs. Engineered patterning and continuous fluid flow in these devices has allowed culturing of intestinal cells bearing physiologically relevant features and sustained exposure to bacteria while maintaining cellular viability, thereby allowing study of inflammatory bowl diseases. However, existing intestinal cells do not possess all physiologically relevant subtypes, do not possess the repertoire of genetic variations, or allow for study of other important cellular actors such as immune cells. Use of iPSC-derived epithelium, including IBD patient-specific cells, allows for superior disease modeling by capturing the multi-faceted nature of the disease.
    Type: Grant
    Filed: July 31, 2018
    Date of Patent: May 10, 2022
    Assignee: EMULATE, INC.
    Inventors: S. Jordan Kerns, Norman Wen, Carol Lucchesi, Christopher David Hinojosa, Jacob Fraser, Jefferson Puerta, Geraldine Hamilton, Robert Barrett, Clive Svendsen, Daniel Levner, Stephen R Targan, Michael Workman, Dhruv Sareen, Uthra Rajamani, Magdalena Kasendra
  • Patent number: 11324860
    Abstract: An implantable medical device includes a polymer substrate and at least one nanofiber. The polymer substrate includes a surface portion extending into the polymer substrate from a surface of the substrate. The at least one nanofiber includes a first portion and a second portion. The first portion is interpenetrated with the surface portion of the substrate, and mechanically fixed to the substrate. The second portion projects from the surface of the substrate.
    Type: Grant
    Filed: August 9, 2017
    Date of Patent: May 10, 2022
    Assignee: Cardiac Pacemakers, Inc.
    Inventors: David R. Wulfman, Danielle Frankson, Adeniyi O. Aremu, Angelo Fruci, Gregory J. Sherwood, Mary M. Byron, Joseph T. Delaney, Jr., Adam McGraw
  • Patent number: 11324829
    Abstract: The present invention addresses the problem of providing a novel application of meglumine or a salt thereof. The present invention is an antiseptic agent consisting of meglumine or a salt thereof, and a pharmaceutical composition comprising the antiseptic agent according to the present invention, and pertaining to: a pharmaceutical composition which does not comprise benzalkonium chloride and which is placed in a reusable container; a product that comprises the pharmaceutical composition comprising the antiseptic agent according to the present invention and a reusable container; and a method of improving the antiseptic effect of the pharmaceutical composition by comprising meglumine or a salt thereof in the pharmaceutical composition that has been placed in the reusable container.
    Type: Grant
    Filed: March 13, 2017
    Date of Patent: May 10, 2022
    Assignee: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Toyomi Fujisawa, Koji Sakanaka, Shinya Umezaki
  • Patent number: 11319361
    Abstract: A process is provided for inhibiting symptoms of intestinal dysbiosis in a subject that includes the oral administration to the subject suffering from intestinal dysbiosis an IgA, IgM, or a combination thereof. When administered in a therapeutic quantity based on the subject characteristics and the type of IgA or IgM, symptoms of intestinal dysbiosis in that subject are inhibited. Even non-secretory forms of IgA or IgM are effective when administered orally.
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: May 3, 2022
    Inventor: Michael R. Simon
  • Patent number: 11312775
    Abstract: Methods of treating, preventing, inhibiting, delaying the onset of, or ameliorating a neurological immunity disorder can include administering an effective amount of a compound comprising an antibody or antigen binding fragment of an antibody to a subject in need of treatment, prevention, inhibition, delay of onset, or amelioration of a neurological immunity disorder. The antibody or the antigen binding fragment of an antibody binds specifically to CD49a.
    Type: Grant
    Filed: July 19, 2018
    Date of Patent: April 26, 2022
    Assignee: University of Virginia Patent Foundation
    Inventors: Jonathan Kipnis, Antoine Louveau
  • Patent number: 11306144
    Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 (and optionally cynomolgus monkey, mouse, and/or rat B7-H4) and compositions comprising such antibodies or antigen-binding fragments thereof. In a specific aspect, the antibodies or antigen-binding fragments thereof that specifically bind to human B7-H4 increase T cell proliferation, increase interferon-gamma production, and/or deplete B7-H4 expressing cells via ADCC activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody or antigen-binding fragment thereof that specifically binds to human B7-H4.
    Type: Grant
    Filed: August 23, 2018
    Date of Patent: April 19, 2022
    Assignee: FIVE PRIME THERAPEUTICS, INC.
    Inventors: Charles Kaplan, Derrick Houser, Luis Borges, Gloria Brattich, David Bellovin, Felicia Kemp, Majid Ghoddusi, Nels P. Nielson, Kathy Miller, Maike Schmidt
  • Patent number: 11299528
    Abstract: Methods of treating an autoimmune disease such as rheumatoid arthritis, methods of increasing apoptosis of pro-inflammatory immune cells or synoviocytes, methods of increasing the quantity of the anti-inflammatory regulatory T cells, and methods of slowing the progression of inflammation in a subject include systemically administering to the subject a pharmaceutical composition including an effective amount of a TRAIL-conjugate. Preferably, the TRAIL-conjugate is effective for at least 3 days, more preferably at least 7 days, without being part of a nanocomplex that modulates the circulation half-life or release kinetics of the TRAIL-conjugate. Combination therapies including administering a second active agent, most preferably a TNF-? inhibitor, as well as pharmaceutical composition dosage units including a TRAIL-conjugate and a TNF-? inhibitor in an effective amount for a single once weekly dose for treatment of rheumatoid arthritis are also provided.
    Type: Grant
    Filed: March 11, 2015
    Date of Patent: April 12, 2022
    Assignee: D&D PHARMATECH INC.
    Inventors: Kang Choon Lee, Ha Na Eom
  • Patent number: 11298561
    Abstract: This application describes a method of using gold nanoparticle (GNP)-targeted pulsed laser technology to enhance antibiotic efficacy against multidrug resistant biofilms. The application also teaches a method for treating topic wound infection using GNP-targeted laser therapy combined with antibiotics treatments.
    Type: Grant
    Filed: May 5, 2019
    Date of Patent: April 12, 2022
    Assignee: The United States of America As Represented by the Secretary of the Navy
    Inventor: Nancy Millenbaugh
  • Patent number: 11291685
    Abstract: A polymer nanoparticle includes a polymer having repeating units of formula (I) wherein X, L1, and R1 are as defined herein. Methods of preparing the polymer nanoparticles and compositions comprising the nanoparticles are also disclosed. The polymers nanoparticles described herein are particularly useful for the treatment of bacterial biofilms.
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: April 5, 2022
    Assignee: THE UNIVERSITY OF MASSACHUSETTS
    Inventors: Vincent M. Rotello, Ryan Francis Landis, Akash Gupta
  • Patent number: 11293925
    Abstract: Immunoglobulin light chain proteins are used to generate synthetic fibrils in vitro. The fibrils are mixed with immunoglobulin light chain proteins from a biological sample. In either a direct binding assay, competition assay, or dilution-based competition assay, a signal is detected from the mixture. The intensity of the detectable signal relates to the level of binding between the immunoglobulin light chain proteins to the fibrils and can thus be used to identify amyloidogenic immunoglobulin light chain proteins in a biological sample of the subject and to assess amyloidogenic risk to a subject. For example, the signal intensities from the assays can be used in a comparison to one or more threshold (control) values derived from samples of known light chain types or in the absence of light chains. The comparisons permit identification of amyloidogenic proteins, assessment of amyloidogenic risk, and categorization of the subject into an appropriate “at risk” group.
    Type: Grant
    Filed: October 19, 2018
    Date of Patent: April 5, 2022
    Inventors: Jonathan S. Wall, Emily Martin
  • Patent number: 11285132
    Abstract: Methods and compositions for treating acute myeloid leukemia and diffuse large B cell lymphoma using combinations of venetoclax and indolinone derivatives are provided.
    Type: Grant
    Filed: April 13, 2020
    Date of Patent: March 29, 2022
    Assignee: Oncternal Therapeutics, Inc.
    Inventors: Brian Lannutti, Katayoun Jessen, James Bradley Breitmeyer
  • Patent number: 11288582
    Abstract: Systems and associated methods are described for providing content recommendations. The system accesses a plurality of recommendation algorithms and assigns a plurality of weight values to each prediction algorithm. Then, the system generates a set of candidate weight combinations, such that each candidate combination includes a weight value assigned to each prediction algorithm. Then requests for content items are received over a predetermined period of time. For each combination, the system generates a set of recommended content items and an evaluation metric that is based on matches with requests. Afterwards, the system replaces a candidate combination that resulted in a generation of a lowest evaluation metric. The aforementioned steps are repeated until the evaluation metrics stop improving. Then display identifiers are displayed for a set of recommended content items generated for a candidate combination with the highest evaluation metric.
    Type: Grant
    Filed: March 29, 2019
    Date of Patent: March 29, 2022
    Assignee: Rovi Guides, Inc.
    Inventors: Kyle Miller, Bryan S. Scappini, James W. Lent
  • Patent number: 11278899
    Abstract: The present disclosure relates to the field of digital microfluidics, and provides a microfluidic particle comprising a charged droplet, an intermediate cladding layer, and a dielectric surface layer. The intermediate cladding layer is hydrophobic and coated outside the charged liquid droplet. The dielectric surface layer is hydrophilic and is coated outside the intermediate cladding layer. A microfluidic system is also provided, where the microfluidic system comprises a digital microfluidic chip and the microfluidic particle is disposed above the digital microfluidic chip.
    Type: Grant
    Filed: April 15, 2019
    Date of Patent: March 22, 2022
    Assignees: Beijing BOE Optoelectronics Technology Co., Ltd., BOE TECHNOLOGY GROUP CO., LTD.
    Inventors: Wei Zhao, Chunlei Wang
  • Patent number: 11273225
    Abstract: The present invention relates to inhibitors of C5a activity and their use in the treatment of cutaneous, neutrophilic, inflammatory diseases in a subject.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: March 15, 2022
    Assignee: InflaRx GmbH
    Inventors: Renfeng Guo, Niels R. Riedemann
  • Patent number: 11266718
    Abstract: A method for treating, remedying, or preventing inflammatory skin disorders by administering a therapeutically effective dose of at least one an antagonist of a calcitonin gene-related peptide receptor in a pharmaceutically acceptable formulation. The method for treating, remedying, or preventing an inflammatory skin disorder by administering topically and to the pre-psoriatic rim a therapeutically effective dose of at least one an antagonist of a calcitonin gene-related peptide receptor in a pharmaceutically acceptable formulation.
    Type: Grant
    Filed: May 30, 2020
    Date of Patent: March 8, 2022
    Assignee: NEPSONE EHF
    Inventor: Birkir Sveinsson
  • Patent number: 11261241
    Abstract: Apparatuses, compositions and methods for removing cells which interfere with regenerative processes. The apparatuses, compositions and methods selectively kill partially functional and/or non-functional cells versus functional cells while protecting functional proliferative cells to the extent that, upon removal of the killed cells by disintegration or scavenging, functional cells replace the partially- or non-functional cells.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: March 1, 2022
    Assignee: SIWA Corporation
    Inventor: Lewis S. Gruber
  • Patent number: 11254695
    Abstract: Compounds are provided to modulate the C5a receptor. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: October 23, 2019
    Date of Patent: February 22, 2022
    Assignee: ChemoCentryx, Inc.
    Inventors: Pingchen Fan, Antoni Krasinski, Venkat Reddy Mali, Shichang Miao, Sreenivas Punna, Yang Song, Valentino J. Stella, Yibin Zeng, Penglie Zhang
  • Patent number: 11253858
    Abstract: A system for processing a sample includes a chamber having at least one inlet and at least one outlet, where the chamber is configured to accommodate flow of the sample from the at least one inlet toward the at least one outlet, and an imager array configured to image the flow of the sample in the chamber, where the imager array includes at least one lensless image sensor configurable opposite at least one light source.
    Type: Grant
    Filed: February 27, 2020
    Date of Patent: February 22, 2022
    Assignee: Bioelectronica Corporation
    Inventors: Leonard Sherman, Roger Chen, Jonathan F. Hull
  • Patent number: 11253538
    Abstract: This document provides methods and materials for reducing amyloid beta levels within a mammal (e.g. a mammal having Alzheimer's disease). For example, this document provides methods for using compositions containing a potato polysaccharide preparation to reduce one or more symptoms of Alzheimer's disease. In some cases, a composition containing a potato polysaccharide preparation provided herein can be used to increase binding, sequestration, and/or degradation of CNS-derived amyloid beta polypeptides, thereby inhibiting the formation of neurofibrillary plaques.
    Type: Grant
    Filed: May 4, 2020
    Date of Patent: February 22, 2022
    Assignee: The Research Foundation for The State University of New York
    Inventors: George B. Stefano, Richard M. Kream, Kirk J. Mantione
  • Patent number: 11236176
    Abstract: Compositions and methods of using SerpinF2-binding molecules for preventing and/or reducing organ damage, functional disability or mortality in a patient at risk due to the activity of SerpinF2 and/or plasminogen activators on tissue injury. Also provided are compositions and methods of using SerpinF2-binding molecules for inhibiting hemorrhage, edema, and apoptosis. Methods for the preparation of medicaments for such methods of treatment and prevention are provided.
    Type: Grant
    Filed: March 6, 2014
    Date of Patent: February 1, 2022
    Assignee: Translational Sciences Inc.
    Inventor: Guy L. Reed
  • Patent number: 11231426
    Abstract: The invention relates to compositions and methods for monitoring phagocytic activity (e.g., diseases and conditions relating to phagocytic activity). In particular, the invention relates to compositions and methods for diagnosing, monitoring, and/or assessing risk of neurodegenerative diseases (e.g., AD).
    Type: Grant
    Filed: November 28, 2011
    Date of Patent: January 25, 2022
    Assignee: INVEN2 AS
    Inventors: Tormod Fladby, Lisbeth Johnsen, Hanne Mali Mollergard
  • Patent number: 11230605
    Abstract: The present invention relates to humanized antibodies that specifically bind to human transferrin receptor and their use in treating cancer and inflammatory disorders.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: January 25, 2022
    Assignee: INATHERYS
    Inventors: Pierre Launay, Coralie Belanger, Hervé Souchet
  • Patent number: 11225509
    Abstract: Provided herein are HER2-targeting molecules comprising Shiga toxin A Subunit derived polypeptides having 1) de-immunization and 2) reduced, protease-cleavage sensitivity while retaining Shiga toxin function(s), such as, e.g., potent cytotoxicity via ribosome inhibition. Certain HER2-targeting molecules of the present invention exhibit reduced immunogenic potential in mammals and are well-tolerated by mammals while retaining aforementioned features. The HER2-targeting molecules of the present invention have uses for selectively killing specific cells (e.g., HER positive tumor cells); for selectively delivering cargos to specific cells (e.g., HER positive tumor cells), and as therapeutic and/or diagnostic molecules for treating and diagnosing a variety of conditions, including cancers and tumors involving the expression or over-expression of cell-surface HER2.
    Type: Grant
    Filed: October 16, 2020
    Date of Patent: January 18, 2022
    Assignee: Molecular Templates, Inc.
    Inventors: Eric Poma, Erin Willert, Jack Higgins
  • Patent number: 11219670
    Abstract: Provided herein are, inter alia, compositions and methods for identifying and using agents capable of inhibiting myofibroblast transition as well as methods for treating diseases associated with the same in a subject in need thereof.
    Type: Grant
    Filed: September 5, 2015
    Date of Patent: January 11, 2022
    Assignee: The Johns Hopkins University
    Inventors: David Kim, Harry C. Dietz
  • Patent number: 11219666
    Abstract: In some aspects, the disclosure relates to GDF/BMP antagonists and methods of using GDF/BMP antagonists to treat, prevent, or reduce the progression rate and/or severity of pulmonary hypertension (PH), particularly treating, preventing or reducing the progression rate and/or severity of one or more PH-associated complications. The disclosure also provides methods of using a GDF/BMP antagonist to treat, prevent, or reduce the progression rate and/or severity of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, and right ventricular hypertrophy. The disclosure further provides methods of using a GDF/BMP antagonist to reduce right ventricular systolic pressure in a subject in need thereof.
    Type: Grant
    Filed: August 25, 2020
    Date of Patent: January 11, 2022
    Assignee: ACCELERON PHARMA INC.
    Inventors: Ravindra Kumar, John Knopf
  • Patent number: 11207412
    Abstract: The present invention relates to compositions of highly concentrated protein formulations showing reduced viscosity. The contained proteins in the prepared formulations are stabilized against aggregation and denaturation and are thus sufficiently storage-stable until administration to the patient.
    Type: Grant
    Filed: April 16, 2019
    Date of Patent: December 28, 2021
    Assignee: Merck Patent GmbH
    Inventors: Martin Zillmann, Alexandra Krog, Raphael Guebeli, Tanja Henzler, Christian Hildebrandt
  • Patent number: 11208464
    Abstract: Fusion proteins containing a half-life extension protein, a linker, and a GDF15 protein are described. Also described are nucleic acids encoding the fusion proteins, recombinant cells thereof, compositions comprising the fusion proteins, and methods of using the fusion proteins for treating or preventing metabolic diseases, disorders or conditions.
    Type: Grant
    Filed: May 15, 2019
    Date of Patent: December 28, 2021
    Assignee: Janssen Sciences Ireland Unlimited Company
    Inventors: Anthony Armstrong, Judith Ann Connor, Jennifer Furman, Chichi Huang, Michael J. Hunter, Xiefan Lin-Schmidt, Serena Nelson, Shamina M. Rangwala, Shannon Mullican, Jose Antonio Chavez
  • Patent number: 11204352
    Abstract: There is provided methods of determining tuberculosis (TB) infection status in an individual comprising: (i) providing a sample comprising T-cells; (ii) exposing the sample of (i) to one or more TB antigens; (iii) identifying T-cells in the sample that are CD4 positive and (a) secrete TNF-? without secreting IFN-?; or (b) secrete IFN-? without secreting TNF-?; (iv) identifying those cells of (iii) which are also CCR7 and, CD127 negative; and optionally (v) calculating the cells identified in (iv) as a percentage of those identified in (iii); wherein the identification of cells in (iv) and/or the percentage of T-cells calculated in (v) correlates to TB infection status of the individual, and wherein steps (iii) and (iv) can be carried out either sequentially or simultaneously. There are also provided compositions and kits for use in such methods.
    Type: Grant
    Filed: November 30, 2020
    Date of Patent: December 21, 2021
    Assignee: MJO Innovations Limited
    Inventors: Ajit Lalvani, Katrina Mary Pollock, Graham Taylor, Hilary Sian Whitworth
  • Patent number: 11198739
    Abstract: The present application relates to optimized IgG immunoglobulin variants, engineering methods for their generation, and their application, particularly for therapeutic purposes.
    Type: Grant
    Filed: September 20, 2017
    Date of Patent: December 14, 2021
    Assignee: Xencor, Inc.
    Inventors: Aaron Keith Chamberlain, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Jost Vielmetter, Sean C. Yoder
  • Patent number: 11191833
    Abstract: The present invention relates to a liquid composition comprising polyclonal immunoglobulins, at least one viscosity modulating amino acid, selected from arginine and histidine, and at least one stabilising amino acid, selected from glycine and proline, wherein more than 90% of the polyclonal immunoglobulins are in the form of monomers or dimers and less than 5% in the form of polymers, and wherein the immunoglobulin concentration in the composition is above 160 g/L and the pH is in the range from 5.2 to 5.9. The invention further relates to a liquid composition for use in medical treatment, to amino acids for formulating a highly concentrated polyclonal immunoglobulins as well as a method of formulating.
    Type: Grant
    Filed: June 12, 2017
    Date of Patent: December 7, 2021
    Assignee: OCTAPHARMA AG
    Inventors: Karin Ahrer, Waltraud Kaar, Ulrich Roessl
  • Patent number: 11179478
    Abstract: The present invention relates to the use of at least one tetra functional non-ionic amphiphilic block copolymer as a vehicle for capped or uncapped mRNA for intracellular delivery for gene therapy.
    Type: Grant
    Filed: April 1, 2015
    Date of Patent: November 23, 2021
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE NANTES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventor: Bruno Pitard
  • Patent number: 11180555
    Abstract: The present disclosure is directed to antibodies directed against CD4, compositions thereof, and methods employing such compositions for the prevention, treatment, and/or functional cure of HIV infection. The disclosed antibodies exert potent competitive HIV entry inhibition by binding to domain 1 of CD4 in both cell-free and cell-to-cell systems. The disclosed antibodies also inhibit antigen induced T cell proliferation and cytokine production (IL2 and IFN-gamma) of CD4+ T cells, which is implicated in the pathogenic cycle of pyroptosis. The disclosed antibodies also have the ability to reactivate resting CD4+ T cells, which is particularly useful for reactivating latent reservoirs of HIV in resting T cells to make these cells susceptible to treatment with antiretroviral agents. Reactivation of HIV infected resting CD4+ T cells allows combinational treatment incorporating antibodies of the current invention with HAART in HIV infected patients leading to the functional cure of HIV.
    Type: Grant
    Filed: November 11, 2014
    Date of Patent: November 23, 2021
    Assignee: UBI US HOLDINGS, LLC.
    Inventor: Chang Yi Wang
  • Patent number: 11180556
    Abstract: The present invention provides antibodies directed against ICOS or a derivative thereof which neutralize ICOS engagement on Treg by inhibiting the fixation between ICOS and ICOS-L and abrogate proliferation of Treg induced by plasmacytoid dendritic cells. The present invention further provides antibodies directed against ICOS or a derivative thereof which induce IL-10 and IFN? production, induce CD4? T cells proliferation, reduce Tconv proliferation, and increase the immunosuppressive function of Treg.
    Type: Grant
    Filed: April 23, 2018
    Date of Patent: November 23, 2021
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), INSTITUT JEAN PAOLI & IRENE CALMETTES, UNIVERSITE D'AIX-MARSEILLE, Universite Claude Bernard—Lyon 1, Centre Leon Berard
    Inventors: Julien Faget, Christophe Caux, Christine Menetrier-Caux, Jacques Nunes, Daniel Olive
  • Patent number: 11173197
    Abstract: The present disclosure relates to nanoemulsion vaccine compositions and methods of making and using the same. The disclosed compositions and methods provide a means of treating, preventing, or protecting an individual from anthrax exposure or poisoning.
    Type: Grant
    Filed: July 6, 2016
    Date of Patent: November 16, 2021
    Assignee: BlueWillow Biologics, Inc.
    Inventor: Susan Ciotti
  • Patent number: 11175296
    Abstract: The present disclosure provides a method of determining treatment for cancer comprising identifying the absence of malic enzyme 1 (ME1) and treating with an inducer of ferroptosis.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: November 16, 2021
    Assignee: Washington University
    Inventors: Brian Van Tine, Sara S. Lange, Jeff Kremer
  • Patent number: 11168127
    Abstract: Compositions are described that include colostrum and/or milk replacer combined with pathogen specific avian antibodies. These pathogen specific avian antibodies include antibodies against pathogens causing infections and disease in the digestive tract as well as outside the digestive tract. Feeding regimens and methods for administering the colostrum and/or milk replacer with the pathogen specific avian antibodies result in the presence of IgY antibodies in the serum of a neonatal animal. The IgY antibody in the serum can neutralize pathogens causing infections outside of the digestive tract.
    Type: Grant
    Filed: December 1, 2016
    Date of Patent: November 9, 2021
    Assignee: CAMAS INCORPORATED
    Inventors: Bradley M. Mitteness, Connie Phillips, Jason Hull, Michelle Hawkins, Ky McCraken
  • Patent number: 11155636
    Abstract: The present invention relates to humanised antibodies that bind PRL3.
    Type: Grant
    Filed: June 14, 2017
    Date of Patent: October 26, 2021
    Assignee: Agency for Science, Technology and Research
    Inventor: Qi Zeng
  • Patent number: 11155623
    Abstract: There is disclosed compositions and methods relating to or derived from anti-CTLA4 antibodies. More specifically, there is disclosed fully human antibodies that bind CTLA4, CTLA4-antibody binding fragments and derivatives of such antibodies, and CTLA4-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease requiring either stimulation of immune responses or suppression.
    Type: Grant
    Filed: January 8, 2019
    Date of Patent: October 26, 2021
    Assignee: Sorrento Therapeutics, Inc.
    Inventors: John Dixon Gray, Heyue Zhou
  • Patent number: 11155615
    Abstract: The invention relates to antibodies, and in particular, to antibodies exhibiting specificity for Receptor tyrosine kinase-like Orphan Receptors (ROR), and to uses thereof, for example in the treatment of cancer. The invention extends to polynucleotide and polypeptide sequences encoding the antibodies, and therapeutic uses thereof, and to diagnostic kits comprising these molecules. The invention also extends to antibody-drug conjugates and to uses thereof in therapy.
    Type: Grant
    Filed: May 17, 2016
    Date of Patent: October 26, 2021
    Assignee: EUREKA THERAPEUTICS, INC.
    Inventors: Brian Wong, Emma Masteller, Cheng Liu, Yiyang Xu, Hong Liu, Su Yan, Jingyi Xiang, Pei Wang
  • Patent number: 11147818
    Abstract: Provided herein are pharmaceutical compositions comprising a phosphatidylinositol 3-kinase inhibitor, or pharmaceutically acceptable form thereof, in combination with a second agent, or a pharmaceutically acceptable form thereof, wherein the second agent is chosen from one or more of 1) a checkpoint modulator, 2) an XPO1 inhibitor, 3) an anti-CD19 antibody, 4) a TLR agonist, 5) a STING agonist, or 6) a Flt3 ligand, or a combination thereof. Also provided herein are methods of treatment comprising administration of the compositions, and uses of the compositions, e.g., for treatment of cancer.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: October 19, 2021
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventor: Jeffery L. Kutok
  • Patent number: 11142576
    Abstract: The current invention provides human variable chain framework regions and humanized antibodies comprising the framework regions, the antibodies being specific for integrin ?1. The invention also provides methods for utilizing the antibodies, for example to treat diseases such as cancer.
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: October 12, 2021
    Assignee: Oncosynergy, Inc.
    Inventor: W. Shawn Carbonell
  • Patent number: 11135287
    Abstract: This invention generally relates to cationic oil-in-water emulsions that can be used to deliver negatively charged molecules, such as an RNA molecule. The emulsion particles comprise an oil core and a cationic lipid. The cationic lipid can interact with the negatively charged molecule thereby anchoring the molecule to the emulsion particles. The cationic emulsions described herein are particularly suitable for delivering nucleic acid molecules (such as an RNA molecule encoding an antigen) to cells and formulating nucleic acid-based vaccines.
    Type: Grant
    Filed: March 7, 2019
    Date of Patent: October 5, 2021
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Luis Brito, Andrew Geall, Derek O'Hagan, Manmohan Singh
  • Patent number: 11136338
    Abstract: The present invention relates to compounds of formulae I and H, or pharmaceutically acceptable salts or esters thereof. Further aspects of the invention relate to pharmaceutical compositions and therapeutic uses of said compounds in the treatment of diseases of uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune responses, inappropriate cellular inflammatory responses, or neurodegenerative disorders, preferably tauopathies, even more preferably. Alzheimer's disease.
    Type: Grant
    Filed: April 22, 2020
    Date of Patent: October 5, 2021
    Assignee: LIFEARC
    Inventors: Jon James Winter-Holt, Edward Giles Mciver, Martin Ambler, Stephen Lewis, Joanne Osborne, Kayleigh Webb-Smith
  • Patent number: 11136401
    Abstract: Provided herein are novel anti-LHR chimeric antigen receptor (CAR), cells or compositions comprising the same, vector or plasmid encoding anti-LHR CAR, and methods for producing the same, or using the same for detecting or treating ovarian cancer or prostate cancer. Also provided herein are anti-LHR antibody, compositions comprising the same, nucleic acid sequence encoding the same, and a kit for detecting LHR.
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: October 5, 2021
    Assignee: University of Southern California
    Inventors: Alan L. Epstein, Peisheng Hu, Jacek K. Pinski
  • Patent number: 11137410
    Abstract: Described herein are methods for determining the overall survival of maintenance hemodialysis patients. The methods include measuring low density lipoprotein (LDL) particle size and subfraction concentrations as prognostic tools for early mortality risk detection. For example, the presence of increased very small LDL concentration or decreased LDL particle size in blood-serum serves as a useful means for prognostic risk assessment and monitoring.
    Type: Grant
    Filed: October 29, 2019
    Date of Patent: October 5, 2021
    Assignees: Quest Diagnostics Investments LLC, Los Angeles Biomedical Research Institute
    Inventors: Kamyar Kalantar-Zedeh, Michael P. Caulfield, Wael A. Salameh
  • Patent number: 11124563
    Abstract: The present invention relates to variable domains of a camelid heavy-chain antibodies directed against a phosphorylated tau protein and conjugates thereof. The present invention also relates to the use of these domains or conjugates for treating or diagnosing disorders mediated by neurofibrillary tangles, neuropil threads or dystrophic neurites, such as tauopathies.
    Type: Grant
    Filed: December 2, 2019
    Date of Patent: September 21, 2021
    Assignees: F. HOFFMANN-LA ROCHE AG, INSTITUT PASTEUR, COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Pierre Lafaye, Sylvie Bay, Benoit Delatour, Marc Dhenain, Charles Duyckaerts, Tengfei Li, Matthias Vandesquille, Christian Czech, Fiona Grueninger
  • Patent number: 11123366
    Abstract: The present invention relates to the use of light-emitting, water soluble nanoparticles in the treatment of disorders of the central nervous system.
    Type: Grant
    Filed: December 15, 2015
    Date of Patent: September 21, 2021
    Assignee: Children's Hospital of Orange County
    Inventors: Sharief Taraman, Spyro Mousses
  • Patent number: 11117970
    Abstract: The present invention provides antibodies that bind to the T-cell co-inhibitor ligand programmed death-ligand1 (PD-L1) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to PD-L1. In certain embodiments, the present invention provides multi-specific antigen-binding molecules comprising a first binding specificity that binds to PD-L1 and a second binding specificity that binds to a tumor cell antigen, an infected cell-specific antigen, or a T-cell co-inhibitor. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing PD-L1 activity, thus providing a means of treating a disease or disorder such as cancer or viral infection.
    Type: Grant
    Filed: February 26, 2018
    Date of Patent: September 14, 2021
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Nicholas J. Papadopoulos, Andrew J. Murphy, Gavin Thurston, Ella Ioffe, Elena Burova
  • Patent number: 11110167
    Abstract: The present invention provides a pharmaceutically acceptable composition comprising: particles of inulin; a substance comprising or consisting of one or more pathogen-associated molecular patterns (PAMPs), and an antigen for use inducing or modulating an immune response in a subject, such as modulating an immune response to an antigen or allergen and/or as a vaccine.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: September 7, 2021
    Assignee: VAXINE PTY LTD
    Inventor: Nikolai Petrovsky
  • Patent number: 11097010
    Abstract: The present invention relates to the fields of molecular medicine and targeted delivery of therapeutic or diagnostic agents to cells outside the vascular system and into the parenchymal tissue of organs within the body. More specifically, the present invention relates to the methods used to identify membrane receptors or transporters capable of carrying cargo specifically targeted to the parenchymal tissue of the brain and to in vivo enrichment methods for selecting peptides that are transported across the blood-brain barrier (“BBB”), or analogously, across other membrane containing organs or structures, such as liver, spleen, kidney and tumors.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: August 24, 2021
    Assignee: Ossianix, Inc.
    Inventors: Pawel Stocki, Krzysztof Bartlomiej Wicher, Julia Lynn Rutkowski, Fabrizio Comper, Mykhaylo Demydchuk, Jaroslaw Michal Szary